Fresenius Medical Care (NYSE:FMS) Coverage Initiated at StockNews.com

Investment analysts at StockNews.com started coverage on shares of Fresenius Medical Care (NYSE:FMS) in a report released on Saturday. The firm set a “strong-buy” rating on the stock.

Separately, Morgan Stanley lowered shares of Fresenius Medical Care from an “equal weight” rating to an “underweight” rating in a research report on Monday, January 8th. One analyst has rated the stock with a sell rating, four have issued a hold rating, two have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $32.25.

Fresenius Medical Care Stock Performance

FMS opened at $20.99 on Friday. The company has a market capitalization of $12.31 billion, a price-to-earnings ratio of 22.81, a P/E/G ratio of 1.17 and a beta of 0.95. The business’s 50-day moving average price is $19.59 and its two-hundred day moving average price is $19.55. Fresenius Medical Care has a 1 year low of $16.37 and a 1 year high of $27.72. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.42 and a quick ratio of 1.07.

Fresenius Medical Care (NYSE:FMS) last posted its quarterly earnings data on Tuesday, February 20th. The company reported $0.47 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.36 by $0.11. The business had revenue of $5.37 billion during the quarter, compared to the consensus estimate of $5.32 billion. Fresenius Medical Care had a return on equity of 4.99% and a net margin of 2.56%. Equities analysts expect that Fresenius Medical Care will post 1.49 EPS for the current fiscal year.

Institutional Investors Weigh In On Fresenius Medical Care

Institutional investors and hedge funds have recently made changes to their positions in the stock. O Shaughnessy Asset Management LLC raised its holdings in shares of Fresenius Medical Care by 259.5% in the 3rd quarter. O Shaughnessy Asset Management LLC now owns 92,635 shares of the company’s stock valued at $1,995,000 after purchasing an additional 66,864 shares during the period. Pacer Advisors Inc. increased its position in Fresenius Medical Care by 14,252.1% during the fourth quarter. Pacer Advisors Inc. now owns 488,401 shares of the company’s stock worth $10,173,000 after buying an additional 484,998 shares during the last quarter. QRG Capital Management Inc. bought a new stake in Fresenius Medical Care in the third quarter valued at approximately $676,000. Bruce G. Allen Investments LLC acquired a new stake in shares of Fresenius Medical Care in the fourth quarter valued at approximately $31,000. Finally, Envestnet Asset Management Inc. boosted its stake in shares of Fresenius Medical Care by 362.2% during the 3rd quarter. Envestnet Asset Management Inc. now owns 259,033 shares of the company’s stock worth $5,580,000 after acquiring an additional 202,991 shares during the period. Institutional investors own 8.25% of the company’s stock.

Fresenius Medical Care Company Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.